Navigating New Data in the Breast Cancer Treatment Paradigm

Kevin Kalinsky, MD, MS, discusses his top takeaways from the 2024 ASCO Annual Meeting and 2024 ESMO Congress, as well as where he sees the field of breast cancer evolving into the future.

Aditya Bardia, MD, MPH, FASCO, discusses QOL outcomes among patients with HER2-low and HER2-ultralow breast cancer from the DESTINY-Breast06 trial.

Kevin Kalinsky, MD, MS, discusses future treatment directions with T-DXd in breast cancer, as well as the evolving role of HER2 classification.

T-DXd improved time to deterioration for pain and other subscores, with no decline in overall QOL in HER2 low/ultralow breast cancer.

Nancy U. Lin, MD, discusses the DESTINY-Breast12 trial of T-DXd in patients with HER2-positive metastatic breast cancer with or without brain metastases.

T-DXd showcased overall and intracranial activity in patients with HER2-positive metastatic breast cancer with stable and active brain metastases.

DESTINY-Breast03 and DESTINY-Breast06 showed that T-DXd is a beneficial treatment approach in HER2-positive, -low, and -ultralow metastatic breast cancer.

Paolo Tarantino, MD, discusses updated data from the phase 3 DESTINY-Breast03 trial of trastuzumab deruxtecan in HER2-positive breast cancer.

VK Gadi, MD, PhD, discusses findings from the DESTINY-Breast06 trial and the implications for hormone receptor–positive, HER2-low metastatic breast cancer.

VK Gadi, MD, PhD, discusses primary results from the phase 3 DESTINY-Breast06 trial of trastuzumab deruxtecan in HR-positive, HER2-low breast cancer.

Mark Pegram, MD, discusses implications of and safety data from the primary analysis of the DESTINY-Breast06 trial in HR+/HER2– metastatic breast cancer.